Anti‑inflammatory effects of propofol during cardiopulmonary bypass: A pilot study.
Loading...
Date
2015-10
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Introduction: Propofol has been suggested as a useful adjunct to cardiopulmonary bypass (CPB) because of its
potential protective effect on the heart mediated by a decrease in ischemia-reperfusion injury and inflammation
at clinically relevant concentrations. In view of these potentially protective properties, which modulate many of
the deleterious mechanism of inflammation attributable to reperfusion injury and CPB, we sought to determine
whether starting a low dose of propofol infusion at the beginning of CPB would decrease inflammation as
measured by pro-inflammatory markers. Materials and Methods: We enrolled 24 patients undergoing elective
coronary artery bypass graft (CABG). The study group received propofol at rate of 120 mcg/kg/min immediately
after starting CPB and was maintained throughout the surgery and for the following 6 hours in the intensive
care unit (ICU). The control group received propofol dose of 30-50 mcg/kg/min which was started at the time
of chest closure with wires and continued for the next 6 hours in the ICU. Interleukins (IL) -6, -8 and -10 and
tumor necrosis factor alpha (TNFalpha) were assayed. Result: The most significant difference was in the
level of IL-6 which had a P value of less than 0.06. Starting a low dose propofol early during the CPB was not
associated with significant hemodynamic instability in comparison with the control group. Conclusion: Our
study shows that propofol may be suitable as an anti-inflammatory adjunct for patients undergoing CABG.
Description
Keywords
Cardiopulmonary bypass, Coronary artery bypass graft, Interleukin, Propofol
Citation
Samir A, Gandreti N, Madhere M, Khan A, Brown M, Loomba V. Anti‑inflammatory effects of propofol during cardiopulmonary bypass: A pilot study. Annals of Cardiac Anaesthesia. 2015 Oct; 18(4): 495-501.